Business Context and Reporting Period
Company: Ginkgo Bioworks Holdings, Inc. (NYSE: DNA)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Ginkgo operates in two segments: Cell Engineering (providing R&D services and tools for biological discovery across medicine, agriculture, and industrial biotech) and Biosecurity (providing biomonitoring and analytics services to governments to detect biological threats). The company is in a restructuring phase, having reduced its workforce by over 50% and consolidated facilities to lower operational expenditures.
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenue | $170.2 | $227.0 | ($56.9) |
| Net Loss | ($312.8) | ($547.0) | $234.3 (Improvement) |
| Operating Loss | ($315.3) | ($559.8) | $244.5 (Improvement) |
| Adjusted EBITDA | ($167.0) | ($293.3) | $126.3 (Improvement) |
| Cash & Cash Equivalents | $167.2 | $561.6 | ($394.4) |
| Marketable Securities | $255.4 | $0.0 | $255.4 |
| Total Liquidity | $422.6 | $561.6 | ($139.0) |
| Accumulated Deficit | ($6.15 billion) | ($5.84 billion) | N/A |
Note: Revenue includes non-cash consideration (equity) of $11.6 million in 2025, down from $61.4 million in 2024.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 25% year-over-year. Cell Engineering revenue fell $41.2 million, primarily due to the absence of $45.4 million in non-cash revenue recognized in 2024 from the terminated Motif FoodWorks contract. Biosecurity revenue declined $15.7 million due to reduced government program activity.
- Expense Reduction: Operating expenses decreased significantly by $301.4 million. Research and Development (R&D) expenses dropped $180.3 million, and General and Administrative (G&A) expenses fell $62.9 million, driven by the restructuring plan (workforce reduction and facility consolidation).
- Restructuring Charges: Restructuring charges were $11.4 million in 2025, down from $24.2 million in 2024, as the majority of workforce reductions were completed in 2025.
- Goodwill Impairment: The $47.9 million goodwill impairment recorded in 2024 did not recur in 2025.
- Cash Flow: Net cash used in operating activities improved to $171.1 million in 2025 from $319.6 million in 2024. However, investing activities consumed $240.3 million, primarily due to the purchase of marketable debt securities ($418.6 million).
Guidance, Outlook, and Risks
- Outlook: Management expects R&D and G&A expenses to remain consistent or decline in 2026 as operational overhead stabilizes. The company anticipates expenditures will exceed revenue for the foreseeable future.
- Capital Resources: As of December 31, 2025, the company held $422.6 million in cash and marketable securities, which management believes is sufficient to fund operations for at least the next 12 months. An At-The-Market (ATM) equity offering program was initiated in September 2025, generating $18.1 million in net proceeds by year-end.
- Material Contingencies:
- Google Cloud Partnership: The company amended its strategic AI partnership, reducing future commitments but incurring a $20.9 million contractual liability in 2025 for spending shortfalls. A one-time payment of $14.0 million is due in January 2026 to be released from original obligations.
- Twist Supply Agreement: An amendment converted remaining minimum commitments into non-refundable payments, resulting in an $8.7 million contractual loss in 2025.
- Surety Bond: The company must fund a $47.0 million surety bond in 2026 for a U.S. Government National Laboratory contract, restricting cash until 2029.
- Subsequent Event: On February 26, 2026, the company entered into an agreement to sell substantially all of its Biosecurity segment to a newly formed entity in exchange for approximately 20% equity. The transaction is expected to close in the first half of 2026.
- Risks: Key risks include the inability to achieve profitability, dependence on a limited number of customers (one Cell Engineering customer accounted for 15% of 2025 revenue), supply chain disruptions for critical lab reagents, and the volatility of equity investments held as non-cash consideration.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $422.6 million cash balance against the upcoming $14.0 million Google Cloud payment and the $47.0 million surety bond requirement in 2026.
- Biosecurity Divestiture: Monitor the closing of the Biosecurity segment sale and the resulting financial impact, including the potential reclassification of prior periods as discontinued operations.
- Revenue Quality: Assess the sustainability of revenue growth without the one-time non-cash revenue releases from terminated contracts (Motif, BiomEdit) that inflated prior periods.
- Restructuring Completion: Confirm that the anticipated cost savings from the >50% workforce reduction and facility consolidation are fully realized in 2026 operating results.
- Contractual Liabilities: Review the status of the Google Cloud and Twist contractual liabilities to ensure no additional shortfall penalties are incurred.